gantenerumab
Jump to navigation
Jump to search
Introduction
Investigational Alzheimer drug tested in dominantly inherited Alzheimer's disease with average follow up of 5 years.
Clinical significance
- no evidence of cognitive benefit
- reduces amyldoid plaques & lowers CSF total tau & phosphorylated tau
Mechanism of action
- targets A-beta (beta-amyloid)
Notes
- phase III trials[2]
- gantenerumab did not meet primary endpoint of slowing clinical decline in early Alzheimer's disease[2]
- beta-amyloid removal also was lower than expected[2]
- Rooche announced plans to shut down all clinical trials of gantenerumab in early Alzheimer's disease because the drug had repeatedly failed to demonstrate a significant clinical benefit[3]
More general terms
Additional terms
References
- ↑ George J Investigational Alzheimer's Drug Shows Effects in Inherited Early-Onset Disease MedPage Today June 21,2021 https://www.medpagetoday.com/neurology/alzheimersdisease/93193
Salloway S. et al. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease Nature Medicine (2021) PMID: https://www.ncbi.nlm.nih.gov/pubmed/34155411 https://www.nature.com/articles/s41591-021-01369-8 - ↑ 2.0 2.1 2.2 2.3 Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD) https://www.clinicaltrials.gov/ct2/show/NCT03443973 https://www.clinicaltrials.gov/ct2/show/NCT03444870
George J Alzheimer's Agent Fails; Antiseizure Drug Use Rises; Stress and Post-COVID Outcomes. News and commentary from the world of neurology and neuroscience. MedPage Today November 15, 2022 https://www.medpagetoday.com/neurology/generalneurology/101764 - ↑ 3.0 3.1 Steenhuysen J Roche shutters most trials of Alzheimer's drug after failed trials. Reuters. 2022. Nov 30. https://www.reuters.com/business/healthcare-pharmaceuticals/roche-shutters-most-trials-alzheimers-drug-after-failed-trials-2022-12-01/